AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
Mentions in press and media 9
| Date | Title | Description |
| 11.11.2024 | AlloVir and Kalaris Therapeutics Announce Merger | AlloVir (Nasdaq: ALVR), a Waltham, MA-based allogeneic T cell immunotherapy company, entered into a definitive merger agreement to combine with Kalaris Therapeutics, a Palo Alto, CA-based clinical-stage biopharmaceutical company. Under the ... |
| 11.03.2024 | ALVR DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action – ALVR | NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “C... |
| 22.12.2023 | The clock is ticking, and Cytokinetics is running out of December | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the final edition of this newsletter for 2023. We’re taking a break for the holida... |
| 13.12.2021 | AlloVir : Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting - Form 8-K | AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting Of the 23 high-risk allogeneic hematopoietic cell transplant patients in ... |
| 22.03.2021 | AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021 | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company’s Chief Executive Office... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 30.05.2019 | Houston biotech company closes $120M Series B, Chevron taps local startup for program, and more innovation news | Big things are happening in Houston — from a $120 million close to the U.S. Department of Energy picking a Houston-area company for nuclear energy research. Here are the highlights of Houston innovation news you might have missed. Need more... |
| 22.05.2019 | ElevateBio names AlloVir as its first portfolio company | Based in Houston, AlloVir is developing allogeneic cell therapies for viral diseases and is planning Phase III studies for its lead product candidate, Viralym-M, within the next 12 months. The cell therapy is being developed for six viruses... |
| - | ElevateBio names AlloVir as its first portfolio company | A company set up to take biomedical research from academia and build companies around it has revealed its first portfolio company. ElevateBio, a Cambridge, Massachusetts-based holding company focused on cell and gene therapies, named AlloVi... |